Humana Inc.’s Stock Price Skyrockets to $431.87, Boasting an Impressive 11.56% Increase

Humana Inc. (HUM)

431.87 USD +44.75 (+11.56%) Volume: 4.99M

Humana Inc.’s stock price has experienced a significant rise, currently trading at 431.87 USD, reflecting a robust surge of +11.56% in the latest trading session. With a trading volume of 4.99M shares, the healthcare company has exhibited a remarkable YTD increase of +68.61%, demonstrating its strong market performance.

Latest developments on Humana Inc.

Humana Inc. stock prices surged today after the health insurer topped the 2027 Medicare star ratings, leading to a significant improvement in its Medicare Advantage ratings. The company’s shares jumped 12% following the news, with 95% of its Medicare Advantage members now in 4-star plans for 2027. This positive development sparked bullish repricing, causing the stock to hit a 52-week high. Analysts are optimistic about Humana’s Medicare Advantage prospects, with upgrades and bullish calls from top firms like Baird and Barclays. The company’s strong performance in Medicare Advantage ratings has positioned it as a leader in the managed care sector, outperforming competitors and affirming its full-year adjusted earnings outlook for 2026.

Humana Inc. on Smartkarma

Analysts at Baptista Research on Smartkarma have provided bullish insights on Humana Inc, highlighting the company’s strategic initiatives and financial performance. In their report titled “Humana’s 600,000-Member Reset — Can It Restore 3% Medicare Advantage Margins?”, they note that Humana Inc. has been maintaining positive momentum in key operational and financial metrics. The company’s focus on enhancing product and customer experience, advancing clinical excellence, and optimizing capital allocation, particularly in growth areas like Medicaid and its CenterWell platform, has supported its membership growth and growth ambitions.

In another report by Baptista Research on Smartkarma, analysts continue to express bullish sentiment towards Humana Inc. in their report “Humana’s CenterWell Expansion Could Reshape Its Long-Term Care Delivery Model!”. The analysts acknowledge the company’s stable start to 2026 and its commitment to returning to a sustainable Medicare Advantage margin of at least 3% by 2028. With a focus on managing growth dynamics and membership retention, Humana Inc. aims to address the gap between medical cost trends and program funding while reshaping its long-term care delivery model through initiatives like the expansion of its CenterWell platform.

A look at Humana Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Humana Inc. is positioned well for the long-term future based on the Smartkarma Smart Scores. With a high score in Value and Momentum, the company is seen as having strong potential for growth and stability. The Value score indicates that the company is trading at an attractive price relative to its fundamentals, while the Momentum score suggests that Humana is experiencing positive trends in stock price. These factors bode well for the company’s outlook in the coming years.

Although Humana Inc. may not score as high in Growth and Dividend, its Resilience score of 3 indicates that the company is able to weather economic downturns and challenges. This, coupled with its strong Value and Momentum scores, suggests that Humana is a solid investment option for those looking for long-term growth and stability in the managed health care sector.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma